3.86
price down icon3.50%   -0.14
after-market Dopo l'orario di chiusura: 3.86
loading
Precedente Chiudi:
$4.00
Aprire:
$3.96
Volume 24 ore:
1.29M
Relative Volume:
1.27
Capitalizzazione di mercato:
$347.02M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-6.8929
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
-11.06%
1M Prestazione:
+2.12%
6M Prestazione:
-27.85%
1 anno Prestazione:
+108.65%
Intervallo 1D:
Value
$3.71
$4.0386
Intervallo di 1 settimana:
Value
$3.71
$4.3763
Portata 52W:
Value
$1.75
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Nome
Corvus Pharmaceuticals Inc
Name
Telefono
(650) 900-4520
Name
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Name
Dipendente
31
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
CRVS's Discussions on Twitter

Confronta CRVS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
3.86 347.02M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-02 Iniziato H.C. Wainwright Buy
2023-08-18 Iniziato Oppenheimer Outperform
2021-12-01 Ripresa Jefferies Buy
2021-05-27 Iniziato Cantor Fitzgerald Overweight
2021-02-10 Downgrade Mizuho Buy → Neutral
2019-09-12 Iniziato Mizuho Buy
2019-05-29 Iniziato ROTH Capital Buy
2017-08-24 Aggiornamento Credit Suisse Underperform → Neutral
2017-05-01 Downgrade Credit Suisse Neutral → Underperform
2016-04-18 Iniziato Credit Suisse Outperform
2016-04-18 Iniziato Guggenheim Buy
Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

pulisher
Jun 18, 2025

Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView

Jun 11, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 10, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire

Jun 04, 2025
pulisher
May 28, 2025

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 20, 2025
pulisher
May 20, 2025

CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com

May 20, 2025
pulisher
May 13, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World

May 13, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Spotlight On Top Penny Stocks For May 2025 - simplywall.st

May 12, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals’ (CRVS) Outperform Rating Reiterated at Oppenheimer - Defense World

May 12, 2025
pulisher
May 10, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 09, 2025
pulisher
May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 09, 2025
pulisher
May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable

May 09, 2025
pulisher
May 09, 2025

Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results - Investing.com

May 09, 2025
pulisher
May 09, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo

May 09, 2025
pulisher
May 09, 2025

Corvus: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga

May 09, 2025
pulisher
May 09, 2025

Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com

May 09, 2025
pulisher
May 09, 2025

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire

May 08, 2025

Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Corvus Pharmaceuticals Inc Azioni (CRVS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
MILLER RICHARD A MD
President and CEO
May 07 '25
Option Exercise
3.50
559,073
1,956,756
1,136,707
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):